Summary
Pramlintide Acetate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 1 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 1 Diabetes. ClinicalTrials.gov lists 8 registered trials linking Pramlintide Acetate to Type 1 Diabetes: 5 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT01269047). The largest enrolment is 1297 participants (NCT00229658). Registration activity spans 2005 to 2022. No published literature item is linked to Pramlintide Acetate and Type 1 Diabetes in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Type 1 Diabetes Mellitus ranks 324 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Essentially zero for established T1DM (honeymoon phase occurs in 50-60% after diagnosis but lasts 3-12 months then ends); the disease is permanent autoimmune destruction of beta cells.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 39.0 (trials 19.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 5 completed, 3 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | CALCR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01269047 | Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia 2009 | completed | Phase 4 | 37 |
| NCT00502138 | A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes 2007 | completed | Phase 4 | 12 |
| NCT04972175 | Safety and Efficacy of BC LisPram 2021 | status unknown | Phase 1 | 16 |
| NCT05199714 | A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes 2022 | completed | Not applicable | 12 |
| NCT00489645 | Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide 2005 | completed | Not applicable | 27 |
| NCT00229658 | An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes 2005 | completed | Not applicable | 1,297 |
| NCT00790699 | Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port 2009 | terminated | Not applicable | 31 |
| NCT01434862 | Pramlintide Combined With Model Predictive Control Algorithm 2011 | terminated | Not applicable | 2 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CALCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Pramlintide Acetate approved for Type 1 Diabetes?
Pramlintide Acetate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 1 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 1 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Pramlintide Acetate in clinical trials for Type 1 Diabetes?
ClinicalTrials.gov lists 8 registered trials linking Pramlintide Acetate to Type 1 Diabetes: 5 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT01269047). The largest enrolment is 1297 participants (NCT00229658). Registration activity spans 2005 to 2022.
What does the evidence show for Pramlintide Acetate in Type 1 Diabetes?
Pramlintide Acetate has 5 completed registered trials for Type 1 Diabetes but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CALCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.